FIGURE 2.

Total numbers and stage distributions for breast, non-small-cell lung (nsclc), and colorectal cancers.

^a Canadian Cancer Statistics 2005 ¹.

^b Estimated at 80% of the 22,200 patients diagnosed with all types of lung cancer ²⁶.

^c Stage distribution and future relapses were derived from the literature for breast ¹⁷, colorectal ¹⁹, and nsclc ⁷ cancers.

^d Lifetime relapses represent the number of patients diagnosed with early-stage (i–iii) cancer (nonmetastatic) multiplied by the expected lifetime risk of relapse for these patients. The estimated numbers for nsclc represent patients with local and distant relapses, because these patients were considered potential candidates for bevacizumab. The estimated numbers for breast and colorectal cancers reflect patients with distant relapses only, because these patients were assumed to be eligible for palliative trastuzumab or bevacizumab monoclonal antibody therapy.